Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 922

1.

Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.

Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4453-E4462. doi: 10.1073/pnas.1800550115. Epub 2018 Apr 19.

PMID:
29674449
2.

Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.

Mengistu M, Tang AH, Foulke JS Jr, Blanpied TA, Gonzalez MW, Spouge JL, Gallo RC, Lewis GK, DeVico AL.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9893-E9902. doi: 10.1073/pnas.1705074114. Epub 2017 Oct 30.

3.

Time to Go Back to the Original Name.

Gallo RC, Willems L, Tagaya Y.

Front Microbiol. 2017 Sep 22;8:1800. doi: 10.3389/fmicb.2017.01800. eCollection 2017. No abstract available.

4.

The Exceptional Oncogenicity of HTLV-1.

Tagaya Y, Gallo RC.

Front Microbiol. 2017 Aug 2;8:1425. doi: 10.3389/fmicb.2017.01425. eCollection 2017. Review.

5.

Mark Wainberg.

Richman DD, Gallo RC.

Curr Opin HIV AIDS. 2017 Sep;12(5):423-424. doi: 10.1097/COH.0000000000000394. No abstract available.

PMID:
28771448
6.

Anti-inflammatory effects of H2S during acute bacterial infection: a review.

Benedetti F, Curreli S, Krishnan S, Davinelli S, Cocchi F, Scapagnini G, Gallo RC, Zella D.

J Transl Med. 2017 May 10;15(1):100. doi: 10.1186/s12967-017-1206-8. Review.

7.

Characterization of cytopathic factors through genome-wide analysis of the Zika viral proteins in fission yeast.

Li G, Poulsen M, Fenyvuesvolgyi C, Yashiroda Y, Yoshida M, Simard JM, Gallo RC, Zhao RY.

Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):E376-E385. doi: 10.1073/pnas.1619735114. Epub 2017 Jan 3.

8.

Screening transplant donors for HTLV-1 and -2.

Gallo RC, Willems L, Hasegawa H; Global Virus Network’s Task Force on HTLV-1.

Blood. 2016 Dec 29;128(26):3029-3031. doi: 10.1182/blood-2016-09-739433. Epub 2016 Nov 9. Review. No abstract available.

9.

Reducing the global burden of HTLV-1 infection: An agenda for research and action.

Willems L, Hasegawa H, Accolla R, Bangham C, Bazarbachi A, Bertazzoni U, Carneiro-Proietti AB, Cheng H, Chieco-Bianchi L, Ciminale V, Coelho-Dos-Reis J, Esparza J, Gallo RC, Gessain A, Gotuzzo E, Hall W, Harford J, Hermine O, Jacobson S, Macchi B, Macpherson C, Mahieux R, Matsuoka M, Murphy E, Peloponese JM, Simon V, Tagaya Y, Taylor GP, Watanabe T, Yamano Y.

Antiviral Res. 2017 Jan;137:41-48. doi: 10.1016/j.antiviral.2016.10.015. Epub 2016 Nov 11. Review.

10.

Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.

Carroll VA, Lafferty MK, Marchionni L, Bryant JL, Gallo RC, Garzino-Demo A.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13168-13173. Epub 2016 Oct 31.

11.

Shock and kill with caution.

Gallo RC.

Science. 2016 Oct 14;354(6309):177-178. No abstract available.

PMID:
27738158
12.

Extracellular vesicles and viruses: Are they close relatives?

Nolte-'t Hoen E, Cremer T, Gallo RC, Margolis LB.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9155-61. doi: 10.1073/pnas.1605146113. Epub 2016 Jul 18.

13.

An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Schwartz JA, Prado I, Misamore J, Weiss D, Francis J, Pal R, Huaman M, Cristillo A, Lewis GK, Gallo RC, DeVico AL, Fouts TR.

Clin Vaccine Immunol. 2016 Jul 5;23(7):618-27. doi: 10.1128/CVI.00115-16. Print 2016 Jul.

14.

Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.

Dolcetti R, Giagulli C, He W, Selleri M, Caccuri F, Eyzaguirre LM, Mazzuca P, Corbellini S, Campilongo F, Marsico S, Giombini E, Muraro E, Rozera G, De Paoli P, Carbone A, Capobianchi MR, Ippolito G, Fiorentini S, Blattner WA, Lu W, Gallo RC, Caruso A.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14331-6. doi: 10.1073/pnas.1514748112. Epub 2015 Nov 2. Erratum in: Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):E7033.

15.

Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015).

DeVico AL, Lewis GK, Gallo RC.

Philos Trans R Soc Lond B Biol Sci. 2015 Nov 5;370(1681). pii: 20150199. doi: 10.1098/rstb.2015.0199. No abstract available.

16.

Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.

Heredia A, Le N, Gartenhaus RB, Sausville E, Medina-Moreno S, Zapata JC, Davis C, Gallo RC, Redfield RR.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9412-7. doi: 10.1073/pnas.1511144112. Epub 2015 Jul 13.

17.

Developing a Successful HIV Vaccine.

Gallo RC.

J Infect Dis. 2015 Jul 15;212 Suppl 1:S40-1. doi: 10.1093/infdis/jiv069.

18.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2413.

19.

The Global Virus Network's testimony on Ebola to the U.S. Senate.

Gallo RC.

F1000Res. 2014 Dec 15;3:307. doi: 10.12688/f1000research.5954.1. eCollection 2014.

20.

HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.

Thomas MA, Tuero I, Demberg T, Vargas-Inchaustegui DA, Musich T, Xiao P, Venzon D, LaBranche C, Montefiori DC, DiPasquale J, Reed SG, DeVico A, Fouts T, Lewis GK, Gallo RC, Robert-Guroff M.

Virology. 2014 Dec;471-473:81-92. doi: 10.1016/j.virol.2014.10.001. Epub 2014 Oct 28.

21.

A historical personal perspective on human retroviruses and their infection of T cells.

Gallo RC.

Transfusion. 2015 Jan;55(1):1-9. doi: 10.1111/trf.12935. Epub 2014 Nov 21. No abstract available.

PMID:
25413015
22.

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21. doi: 10.1073/pnas.1413550111. Epub 2014 Oct 27. Review.

23.

Screening test for HTLV-III (AIDS agent) antibodies: specificity, sensitivity, and applications.

Weiss SH, Goedert JJ, Sarngadharan MG, Bodner AJ; AIDS Seroepidemiology Collaborative Working Group, Gallo RC, Blattner WA.

JAMA. 2014 Jul 23-30;312(4):442. doi: 10.1001/jama.2013.279636. No abstract available.

PMID:
25038372
24.

Sulfur compounds block MCP-1 production by Mycoplasma fermentans-infected macrophages through NF-κB inhibition.

Benedetti F, Davinelli S, Krishnan S, Gallo RC, Scapagnini G, Zella D, Curreli S.

J Transl Med. 2014 May 24;12:145. doi: 10.1186/1479-5876-12-145.

25.

B cell lymphoma in HIV transgenic mice.

Curreli S, Krishnan S, Reitz M, Lunardi-Iskandar Y, Lafferty MK, Garzino-Demo A, Zella D, Gallo RC, Bryant J.

Retrovirology. 2013 Aug 28;10:92. doi: 10.1186/1742-4690-10-92.

26.

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78. doi: 10.1073/pnas.1217609110. Epub 2012 Dec 13.

27.

Active and passive anticytokine immune therapies: current status and development.

Le Buanec H, Bensussan A, Bagot M, Gallo RC, Zagury D.

Adv Immunol. 2012;115:187-227. doi: 10.1016/B978-0-12-394299-9.00007-2. Review.

PMID:
22608260
28.

Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases.

Cocchi F, DeVico AL, Lu W, Popovic M, Latinovic O, Sajadi MM, Redfield RR, Lafferty MK, Galli M, Garzino-Demo A, Gallo RC.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5411-6. doi: 10.1073/pnas.1202240109. Epub 2012 Mar 19.

29.

Research and discovery of the first human cancer virus, HTLV-1.

Gallo RC.

Best Pract Res Clin Haematol. 2011 Dec;24(4):559-65. doi: 10.1016/j.beha.2011.09.012. Epub 2011 Nov 16. Review.

PMID:
22127321
30.

IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells.

Le Buanec H, Gougeon ML, Mathian A, Lebon P, Dupont JM, Peltre G, Hemon P, Schmid M, Bizzini B, Künding T, Burny A, Bensussan A, Amoura Z, Gallo RC, Zagury D.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18995-9000. doi: 10.1073/pnas.1113301108. Epub 2011 Nov 7.

31.

Evolution of SIV toward RANTES resistance in macaques rapidly progressing to AIDS upon coinfection with HHV-6A.

Biancotto A, Grivel JC, Lisco A, Vanpouille C, Markham PD, Gallo RC, Margolis LB, Lusso P.

Retrovirology. 2009 Jul 2;6:61. doi: 10.1186/1742-4690-6-61.

32.

Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.

Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.

Antiviral Res. 2009 Jul;83(1):86-9. doi: 10.1016/j.antiviral.2009.02.199. Epub 2009 Mar 9.

PMID:
19501260
33.

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model.

Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B, Gallo RC, Koutouzov S.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5294-9. doi: 10.1073/pnas.0900615106. Epub 2009 Mar 11.

34.

Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, Redfield RR, DeVico AL, Gallo RC, Lewis GK.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7. doi: 10.1073/pnas.0813392106. Epub 2009 Feb 18.

35.

Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20476-81. doi: 10.1073/pnas.0810843106. Epub 2008 Dec 15.

36.

Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.

Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM.

J Virol. 2009 Jan;83(1):304-13. doi: 10.1128/JVI.01606-08. Epub 2008 Oct 22.

37.

Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients.

Lehmann C, Harper JM, Taubert D, Hartmann P, Fätkenheuer G, Jung N, van Lunzen J, Stellbrink HJ, Gallo RC, Romerio F.

J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):522-30. doi: 10.1097/QAI.0b013e31817f97cf.

PMID:
18645522
38.

[Kinoids: a novel generation of specific immune therapy against cytokines].

Bensussan A, Bizzini B, Pouletty P, Gallo RC, Zagury D.

Med Sci (Paris). 2008 Mar;24(3):306-13. doi: 10.1051/medsci/2008243306. Review. French.

39.

Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.

DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17477-82. Epub 2007 Oct 23.

40.

Functional and morphologic characterization of human T cells continuously grown in vitro. J. Immunol. 1977. 119: 131-138.

Ruscetti FW, Morgan DA, Gallo RC.

J Immunol. 2007 Aug 1;179(3):1415-22. No abstract available.

41.

CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.

Heredia A, Gilliam B, DeVico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, Redfield RR.

AIDS. 2007 Jun 19;21(10):1317-22.

PMID:
17545708
42.

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR.

Antimicrob Agents Chemother. 2007 Jul;51(7):2489-96. Epub 2007 May 7.

43.

Human herpesvirus 6A accelerates AIDS progression in macaques.

Lusso P, Crowley RW, Malnati MS, Di Serio C, Ponzoni M, Biancotto A, Markham PD, Gallo RC.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5067-72. Epub 2007 Mar 14.

44.

VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.

Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D, Uzan G.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2837-42. Epub 2007 Feb 14.

45.

A perspective on human herpes virus 6 (HHV-6).

Gallo RC.

J Clin Virol. 2006 Dec;37 Suppl 1:S2. No abstract available.

PMID:
17276365
46.

A plea for justice for jailed medical workers.

Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA.

Science. 2006 Nov 10;314(5801):924-5. Epub 2006 Oct 24. No abstract available.

PMID:
17062652
47.

A reflection on HIV/AIDS research after 25 years.

Gallo RC.

Retrovirology. 2006 Oct 20;3:72.

48.

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM.

J Virol. 2006 Sep;80(18):9134-43.

49.

HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation.

Yadav A, Pati S, Nyugen A, Barabitskaja O, Mondal P, Anderson M, Gallo RC, Huso DL, Reid W.

Virology. 2006 Sep 30;353(2):357-65. Epub 2006 Jul 10.

50.

Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.

Kish-Catalone TM, Lu W, Gallo RC, DeVico AL.

Antimicrob Agents Chemother. 2006 Apr;50(4):1497-509.

Supplemental Content

Loading ...
Support Center